Management and working modes of outpatient pharmacies amid routine COVID-19 epidemic prevention

doi:10.19803/j.1672-8629.2022.01.22

Abstract

Abstract: Objective To explore the ways in which outpatient pharmacies of hospitals work in order to finish the daily work and ensure the safety of drugs amid the COVID-19 pandemic Methods By reference to the related guidelines and literature and based on the actualities in our hospital, important measures for prevention and control of the pandemic in the daily work of the outpatient pharmacy were clarified. Meanwhile, efforts were made to change the working mode in the outpatient pharmacy. Results In the outpatient pharmacy, some prevention measures were formulated while the working mode was changed accordingly. Conclusion Amid the routine epidemic prevention of COVID-19, the measures that have been taken and changes that have been brought into the working mode in the outpatient pharmacy can ensure the safety of patients and pharmacists. Pharmaceutical care in the outpatient pharmacy has been improved.

Key words: COVID-19, routine epidemic prevention, outpatient pharmacy, management mode, prevention and control measures

CLC Number:

R969.3

ZHAO Xuan, GUO Jing, REN Shuang, ZHEN Jiancun. Management and working modes of outpatient pharmacies amid routine COVID-19 epidemic prevention[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 100-102.

References

[1] General Office of National Health Commission. Novel coronavirus pneumonia control protocol (8th edition)[EB/OL]. (2021-05-14)[2020-06-14]. http://www.nhc.gov.cn/jkj/s3577/202105/6f1e8ec6c4a540d99fafef52fc86d0f8.shtml.
[2] Bureau for Disease Control and Prevention. Announcement of the National Health Commission of the People's Republic of China (No.1, 2020)[EB/OL]. (2020-01-20)[2021-06-14]. http://www.nhe.gov.cn/jkj/s7916/202001/44a3b8245e8049d2837a4f27529cd386.shtml.
[3] WU WY, XIAO X, WU JR.The practice and thinking of pharma-covigilance at the municipal level under COVID-19[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(9): 688-691.
[4] General Office of National Health Commission. Guidelines for novel coronavirus infection prevention and control in healthcare institutions (1st Edition)[EB/OL]. (2020-01-23)[2021-06-14]. http://www.nhe.gov.cn/yzygj/s7659/202001/b91fdab7c304431eb082d67847d27e14.shtml.
[5] General Office of the National Health Commission. Guidelines on the scope of use of common medical protective products in the prevention and control of coronavirus infection (Trial)[EB/OL]. (2020-01-27)[2021-06-13]. http://www.nhe.gov.cn/xcs/zhengcwj/202001/e71c5de925a64eafbe1ce790debab5c6.shtml.
[6] ZHAO RS, YANG YH, YANG L, et al.An outbreak of the SARS-CoV-2 coronavirus: information and pilot guidance for pharmacists and pharmacy workers[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2020, 55(4): 249-267.
[7] CHEN LF, XIAO Y, YU Y, et al.Prevention and control measures of the hospital pharmacy in fever clinic during the coronavirus disease 2019 epidemic[J]. China Pharmaceuticals(中国药业), 2020, 29(5): 18-22.
[8] Ministry of Health, PRC. Measures for waste management in medical and health institutions (Decree No. 36 of the Ministry of Health of the People's Republic of China)[EB/OL]. (2003-10-15)[2021-06-13]. http://www.gov.cn/gongbao/content/2004/content_62768.html.
[9] The State Council of the People's Republic of China. Regulations on management of medical waste(Decree No. 360 of the Ministry of Health of the People's Republic of China)[EB/OL].(2003-06-16)[2021-11-11]. http://www.gov.cn/zhengce/content/2008-03/28/content_6387.htm.

[1]	ZHANG Jingsheng, JI Zuen, PANG Bo, XU Yingli, CAO Shan, ZHANG Yu, SUN Qiyue, SUN Jing, LI Shuran, ZHANG Wei, ZHAO Ronghua, CUI Xiaolan. Discussion on traditional Chinese medicine theory and modern pharmacology of Xuanfei Baidu decoction for treating novel coronavirus infection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 55-58.
[2]	LI Shuran, GUO Shanshan, JI Zuen, ZHANG Wei, CUI Xiaolan. Research status of cognitive dysfunction after SARS-CoV-2 infection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 59-64.
[3]	LI Jing, XU Ye, LIU Ranjia, PAN Chen, CUI Xiangli. Adverse reactions in patients with COVID-19 after using tocilizumab [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1049-1053.
[4]	YANG Qiuyue, SU Jun, ZHANG Xue, XIE Jiangan. Adverse events associated with the three US licensed COVID-19 vaccines based on VAERS database [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1141-1147.
[5]	GE Ziruo, TIAN Di, WANG Aibin, ZHANG Tingyu, REN Xingxiang, QIAN Fang, LI Xingwang, CHEN Zhihai. Therapeutic effect of interferon atomization against COVID-19 [J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 733-739.
[6]	WANG Tiezhu. Signal detection and analysis of adverse reaction of hydroxychloroquine sulfate induced visual impairment [J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 657-660.
[7]	ZHAO Xuan, GUO Jing, MEI Long, ZHANG Wei. Automatic dispensing system on influence of work efficiency of outpatient pharmacy and the safety of prevention and control of COVID-19 [J]. Chinese Journal of Pharmacovigilance, 2022, 19(5): 564-567.
[8]	YANG Fan, MA Haiping, YOU Mengru, LIAO Sha, LIU Lan, ZHU Jun. Applications of antiviral drugs in 456 patients with COVID-19 [J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 413-416.
[9]	ZHOU Boya, YUAN Sisi, FENG Xin. Research progress in effects of lopinavir / ritonavir used by lactating females on sucklings [J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 296-301.
[10]	GUO Jun, REN Dan, YE Long, ZHAO Rongxiang, WANG Yu, YU Jing. Spontaneous muscular hemorrhage induced by warfarin tablets in a child [J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 339-341.
[11]	XIONG Jing, LIU Yi, LIU Zhaoxia, LI Jie, ZHANG Caiyu, WU Xiangxiang, HE Lan. Development of the first national reference substance of ritonavir as a candidate drug against COVID-19 [J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 137-141.
[12]	LI Tianyu, JIA Yijiang, WANG Yuji, WANG Jinhui, LI Ye. Research progress of treatment drugs for SARS-CoV-2 [J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1266-1271.
[13]	ZHAO Zhe, ZHANG Qing, GE Ziruo, ZHANG Wei, CHEN Zhihai. Giant progress in small molecule antiviral drugs for SARS-CoV-2 [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 1-6.
[14]	XIONG Jing, YAN Jing, LIU Yi, LIU Yang, HE Lan. Development of the first national reference substance of favipiravir as a candidate drug against COVID-19 [J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 52-56.
[15]	WU Fei, LI Min, FANG Yuting, CHEN Yongwu, SHEN Aizong. Active Monitoring of Adverse Drug Reactions Caused by Lopinavir/ritonavir in Treating Coronavirus Disease 2019 [J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 105-109.